Table 2. Survival data of studies included in the meta-analysis.
| Study | Year | Cancer type | Detection method | Sample size | Survival information | HR statistic | |||
|---|---|---|---|---|---|---|---|---|---|
| Overall survival (OS) | Other survival | ||||||||
| Univariate analysis | Multivariate | Univariate analysis | Multivariate | ||||||
| Liu et al [13] | 2016 | HCC | RT-qPCR | 129 | 0.59 (0.34–1.03) (E) | NA | 0.51 (0.30–0.89) (E)1 | NA | Survival curve |
| Li et al [10] | 2018 | OSC | RT-qPCR | 84 | 2.636 (1.458–4.767) | 2.162 (1.158–4.037) | NA | NA | Data in paper |
| Zhang et al [11] | 2020 | GC | RT-qPCR | 71 | 2.07 (1.33–3.24) (E) | NA | NA | NA | Survival curve |
| Liang et al [17] | 2020 | glioma | RT-qPCR | 187 | 1.36 (0.90–2.07) (E) | 5.358 (1.775–8.569) | 1.69 (1.15–2.49) (E)2 | 6.323 (2.213–9.934)2 | Both of two |
| Guo et al [16] | 2015 | CRC | RT-qPCR | 187 | 151 (0.98–2.32) (E) | 2.371 (1.42–2.739) | NA | NA | Both of two |
| Li et al [14] | 2019 | HCC | RT-qPCR | 73 | 12.456 (1.607–96.543) | 10.376 (1.284–83.836) | 7.484 (3.398–16.486)3 | 6.411 (2.859–14.375)3 | Data in paper |
| Yang et al [20] | 2018 | CRC | RT-qPCR | 80 | 1.32 (0.80–2.17) (E) | NA | NA | NA | Survival curve |
| Liu et al [21] | 2016 | HCC | RT-qPCR | 126 | 1.92 (1.23–2.92) (E) | NA | 2.08 (1.32–3.27) (E)3 | NA | Survival curve |
1
Recurrence-free survival.
2
Progression-free survival.
3
Disease-free survival.
Abbreviations: CRC, colorectal cancer; E, survival data were obtained by using software Engauge Digitizer; GC, gastric cancer; HCC, hepatocellular carcinoma; HR, hazard ratio; NA, not available; OSC, osteosarcoma; RCC, renal cell carcinoma; RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction.